PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players -



Published: October 2013 | Pages: 51 | Format: PDF

GlobalData has released its pharma report, "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Systemic Lupus Erythematosus and Lupus Nephritis Market. The report identifies and analyses the key companies shaping and driving the global Systemic Lupus Erythematosus and Lupus Nephritis market. The report provides insight into the competitive Systemic Lupus Erythematosus and Lupus Nephritis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts. 

 Scope 

 

  •  Investigation of current and future market competition for Systemic Lupus Erythematosus and Lupus Nephritis 
  •  Competitor assessment 
  •  Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. 
  •  Strategic assessment of the Systemic Lupus Erythematosus and Lupus Nephritis sector through market impact analysis, future market scenario and company analysis 

 

 Reasons to buy 

 

  •  Gain a high level view of the trends shaping and driving the Systemic Lupus Erythematosus and Lupus Nephritis Market 
  •  Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. 
  •  Create an effective counter-strategy to gain a competitive advantage against those currently in the market 
  •  What's the next big thing in the global Systemic Lupus Erythematosus and Lupus Nephritis market landscape? Identify, understand and capitalize 

 

 1 Table of Contents 

 1 Table of Contents 6 

 1.1 List of Tables 8 

 1.2 List of Figures 9 

 2 Introduction 10 

 2.1 Catalyst 10 

 2.2 Related Reports 10 

 3 Market Outlook 12 

 3.1 Global Markets 12 

 3.1.1 Forecast 12 

 3.1.2 Drivers and Barriers - Global Issues 19 

 4 Current and Future Players 22 

 4.1 Overview 22 

 4.2 Trends in Corporate Strategy 24 

 4.3 Company Profiles 26 

 4.3.1 GlaxoSmithKline 26 

 4.3.2 Roche 28 

 4.3.3 UCB 31 

 4.3.4 Eli Lilly and Company 33 

 4.3.5 Bristol-Myers Squibb 35 

 4.3.6 Anthera Pharmaceuticals 36 

 4.3.7 ImmuPharma 38 

 4.3.8 Merck Serono 39 

 5 Appendix 41 

 5.1 Bibliography 41 

 5.2 Abbreviations 41 

 5.3 Methodology 43 

 5.4 Forecasting Methodology 43 

 5.4.1 Diagnosed SLE and LN Patients 43 

 5.4.2 Percent Drug-Treated Patients 44 

 5.4.3 Drugs Included in Each Therapeutic Class 44 

 5.4.4 General Pricing Assumptions 44 

 5.4.5 Generic Erosion 45 

 5.5 Physicians and Specialists Included in this Study 45 

 5.6 Primary Research - Prescriber Survey 47 

 5.7 About the Authors 48 

 5.7.1 Analysts 48 

 5.7.2 Global Head of Healthcare 49 

 5.8 About GlobalData 50 

 5.9 Disclaimer 50 

 1.1 List of Tables 

 Table 1: Global Sales Forecasts ($m) for SLE, 2012-2022 14 

 Table 2: Global Sales Forecasts ($m) for LN, 2012-2022 15 

 Table 3: SLE and LN Market - Global Drivers and Barriers, 2012-2022 19 

 Table 4: Key Companies in the SLE and LN Market, 2013 23 

 Table 5: GlaxoSmithKline's SLE and LN Portfolio Assessment, 2013 27 

 Table 6: GlaxoSmithKline SWOT Analysis, 2013 28 

 Table 7: Roche's SLE and LN Portfolio Assessment, 2013 30 

 Table 8: Roche SWOT Analysis, 2013 30 

 Table 9: UCB's SLE and LN Portfolio Assessment, 2013 32 

 Table 10: UCB SWOT Analysis, 2013 32 

 Table 11: Eli Lilly and Company's SLE and LN Portfolio Assessment, 2013 34 

 Table 12: Eli Lilly and Company SWOT Analysis, 2013 34 

 Table 13: BMS' SLE and LN Portfolio Assessment, 2013 35 

 Table 14: BMS SWOT Analysis, 2013 36 

 Table 15: Anthera Pharmaceuticals' SLE and LN Portfolio Assessment, 2013 37 

 Table 16: Anthera Pharmaceuticals SWOT Analysis, 2013 37 

 Table 17: ImmuPharma's SLE and LN Portfolio Assessment, 2013 38 

 Table 18: ImmuPharma SWOT Analysis, 2013 39 

 Table 19: Merck Serono's SLE and LN Portfolio Assessment, 2013 40 

 Table 20: Merck Serono SWOT Analysis, 2013 40 

 Table 21: Number of Physicians Surveyed by Country 47 

 1.2 List of Figures 

 Figure 1: Global Sales for SLE and LN by Region, 2012-2022 16 

 Figure 2: Sales for SLE in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022 17 

 Figure 3: Sales for LN in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022 18 

 Figure 4: Company Portfolio Gap Analysis in SLE and LN, 2012-2022 24